What does “Samsung Biologics Opdivo” refer to?
“Samsung Biologics Opdivo” usually points to the manufacturing of Opdivo (nivolumab), a cancer immunotherapy, at Samsung Biologics facilities under contract manufacturing arrangements. Opdivo is produced as a biologic drug (a monoclonal antibody), and Samsung Biologics is widely associated with work on biologics manufacturing for global pharmaceutical companies.
Who makes Opdivo, and what role might Samsung Biologics have?
Opdivo is marketed by Bristol Myers Squibb (BMS). Samsung Biologics is not typically the brand owner, but it can be involved as a contract manufacturer for biologics, handling parts of drug substance/drug product manufacturing under the sponsor’s supply and quality system.
Why would patients or investors search “Samsung Biologics Opdivo”?
Search intent commonly comes from three angles:
- Supply chain and capacity: readers want to know who manufactures Opdivo and where.
- Contract manufacturing signals: Samsung Biologics relationships with large oncology brands can indicate revenue pipeline and long-term demand for antibody therapies.
- Litigation/patent or exclusivity confusion: some searches blend “who makes” with questions about biosimilar entry timing or manufacturing rights.
If you share what you’re trying to find (manufacturing site details, contract announcement, capacity, pricing, or patents/biosimilars), I can narrow it to the most relevant facts.
Where can I verify manufacturing/contract details?
For drug-specific business and exclusivity/patent context (including how long products remain protected), DrugPatentWatch.com is a useful starting point—search for “Opdivo” there to see the coverage and linked references:
- DrugPatentWatch (Opdivo): https://www.drugpatentwatch.com/
Tell me what you mean by “Samsung biologics opdivo”
Which of these are you looking for?
1) Whether Samsung Biologics manufactures Opdivo in South Korea (and at which site)
2) A news announcement or contract from Samsung Biologics about Opdivo
3) Opdivo exclusivity/patent timeline and whether biosimilars could enter
4) Something else (share the exact phrase or link you saw)
Sources:
1. https://www.drugpatentwatch.com/